Variations in a gene and a protein aggravate the prognosis of one gastric tumor
(Universidad Complutense de Madrid) More than a million people worldwide were diagnosed with stomach cancer in 2018, the fifth most prevalent cancer. The most common gastric tumor is gastric adenocarcinoma, originating in the gastric mucosa. A research team led by the University Complutense of Madrid in Spain has identified 2 biomarkers that help predict the risk of developing the disease, as well as a poorer prognosis: polymorphisms-variations-of the transforming growth factor B1 (TGFB1) gene and the TGFB1 protein. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2021 Category: Cancer & Oncology Source Type: news

PET/MRI biomarkers guide personalized treatment for patients with pancreatic cancer
Positron emission tomography (PET)/MRI has changed how Mayo Clinic specialists treat patients with pancreatic cancer. Mayo Clinic pioneered the use of PET/MRI to manage pancreatic cancer. Now a new study by Ananya Panda, M.B.B.S., and colleagues systematically evaluates the strengths of PET/MRI for pancreatic ductal adenocarcinoma (PDAC). In less than five years, Mayo's PET/MRI practice [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 4, 2021 Category: Databases & Libraries Source Type: news

FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancers
Phase I/II Clinical Trial to Be Initiated in First Quarter 2021 CAMBRIDGE, Mass., Feb. 23, 2021 -- (Healthcare Sales & Marketing Network) -- Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on i... Biopharmaceuticals, Oncology, FDA Elicio Therapeutics, Amphiphile, KRAS, pancreatic ductal adenocarcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2021 Category: Pharmaceuticals Source Type: news

FDA D.I.S.C.O. Burst Edition: FDA Approvals of Xalkori for patients 1-21 years with ALK-positive ALCL and Enhertu for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Is Adenocarcinoma of the Lung an Aggressive Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 3, 2021 Category: General Medicine Source Type: news

Is Intestinal Adenocarcinoma an Aggressive Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 3, 2021 Category: General Medicine Source Type: news

New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
January 28, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings sho...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Researchers probe new territory in treating patients with lung cancer during pandemic
(International Association for the Study of Lung Cancer) On February 27, 2020, the flagship journal of the International Association for the Study of Lung Cancer, the Journal of Thoracic Oncology, published a case study that described two patients from Wuhan, China who recently underwent lung lobectomies for adenocarcinoma and were retrospectively found to have had COVID-19 at the time of surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2021 Category: Cancer & Oncology Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas
On January 15, 2021, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

CRC Risk in Young Adults: Not as High as Previously Reported CRC Risk in Young Adults: Not as High as Previously Reported
Previous studies of colorectal cancer (CRC) included carcinoid tumors as well as colorectal adenocarcinoma, which has inflated estimates of risk, say experts.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - December 31, 2020 Category: Primary Care Tags: Hematology-Oncology News Source Type: news

Incidence of Young - Onset Esophageal Adenocarcinoma Rising
Young - onset esophageal adenocarcinoma presenting at more advanced stages; proportion of advanced stage up from 1975 to 2015 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 28, 2020 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Internal Medicine, Oncology, Journal, Source Type: news

Incidence of Young-Onset Esophageal Adenocarcinoma Rising
MONDAY, Dec. 28, 2020 -- The incidence of young-onset esophageal adenocarcinoma is increasing, and patients present at more advanced stages compared with older patients, according to a study published online Dec. 11 in Cancer Epidemiology,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 28, 2020 Category: Pharmaceuticals Source Type: news

CT radiomics predicts COVID-19 severity, outcome
A machine-learning algorithm based on CT radiomics can help clinicians predict...Read more on AuntMinnie.comRelated Reading: CT radiomics characterizes complex cystic renal lesions Radiomics enables prediction of invasive adenocarcinoma Imaging informatics: More than just AI at RSNA 2020 CT shows its value in the COVID-19 crisis Radiomics can aid management of lung cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 22, 2020 Category: Radiology Source Type: news

Early - Onset CRC Incidence Examined by Histologic Subtype
Adenocarcinomas increasing in most early - onset subgroups; carcinoid tumors increasing more steeply in all age groups (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 21, 2020 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Journal, Source Type: news

Early-Onset CRC Incidence Examined by Histologic Subtype
MONDAY, Dec. 21, 2020 -- Among individuals with early-onset colorectal cancer (EOCRC), adenocarcinoma rates are increasing in specific subgroups, but carcinoid tumors are increasing more steeply in all age groups, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2020 Category: Pharmaceuticals Source Type: news

Incidence of esophageal adenocarcinoma is increasing in younger adults
(American Association for Cancer Research) Esophageal adenocarcinoma is occurring more frequently in adults under age 50, and these younger adults are more likely to be diagnosed at advanced stages. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 16, 2020 Category: International Medicine & Public Health Source Type: news

Prostate Cancer Pathology Not Worse With Delayed Surgery
FRIDAY, Dec. 11, 2020 -- Among men with clinically localized high-risk prostate adenocarcinoma undergoing radical prostatectomy, surgical delay time (SDT) is not associated with a higher risk for adverse pathological features or with worse overall... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2020 Category: Pharmaceuticals Source Type: news

PET/MRI, CT metrics assess pathologic response of pancreas cancer to neoadjuvant therapy
(American Roentgen Ray Society) According to an open-access Editor's Choice article in ARRS' American Journal of Roentgenology (AJR), post-neoadjuvant therapy (NAT) changes in metabolic metrics from PET/MRI and morphologic metrics from CT were associated with pathologic response and overall survival in patients with pancreatic ductal adenocarcinoma (PDA). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2020 Category: Cancer & Oncology Source Type: news

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RARITAN, N.J., December 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. The application marks the first-ever regulatory submission for the treatment of patients with NSCLC with EGFR exon 20 insertion mutations.[1] The Company...
Source: Johnson and Johnson - December 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Unexpected finding reveals new target for aggressive form of lung cancer
(Memorial Sloan Kettering Cancer Center) An MSK team has found that a particular subset of lung adenocarcinomas is aggressive due to a combination of two mutations that allow them to block ferroptosis, a type of cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2020 Category: Cancer & Oncology Source Type: news

What are Potential Problems Associated with Helicobacter pylori?
Discussion Helicobacter pylori (H. pylori) is a microaerophilis, spiral bacterium that is a prevalent human pathogen. How this infection affects individuals is different in adults and children. Overall seroprevalence rate in children world-wide was estimated to be ~33%, but this seroprevalence rate is decreasing in the developed world for both adults and children. It is acquired in childhood and can persist through colonization throughout life if untreated. Fortunately, it often is asymptomatic and generally does not cause serious disease in children. Some serotyping data shows that within families children acquire it more...
Source: PediatricEducation.org - November 23, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Radiomics enables prediction of invasive adenocarcinoma
A machine-learning algorithm based on radiomics features of pure ground-glass...Read more on AuntMinnie.comRelated Reading: CT shows COVID-19 causes lingering lung damage AI reduces missed lung cancers on chest x-ray Can radiomics improve CT lung cancer screening? Could CT lung screening benefit female never-smokers? ISCT: Will AI for CT be radiology's killer app? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 19, 2020 Category: Radiology Source Type: news

' Watch and Wait' Feasible for Some Rectal Cancer Patients
TUESDAY, Nov. 3, 2020 -- A " watch-and-wait " (WW) strategy may be an option for carefully selected patients who achieve a complete response (CR) to neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 3, 2020 Category: Pharmaceuticals Source Type: news

PET/CT with Ga-68 tracer better for cancer patients
By attaching gallium-68 (Ga-68) to a fibroblast activation protein molecule...Read more on AuntMinnie.comRelated Reading: SNMMI: Multicancer radiotracer wins Image of the Year New class of radiotracers targets many cancer types Can radiomics detect pancreatic ductal adenocarcinoma? 2 new PET tracers may best FDG in cancer imaging (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 2, 2020 Category: Radiology Source Type: news

Doubts About Stroma-Targeting Agents in Pancreatic Cancer Doubts About Stroma-Targeting Agents in Pancreatic Cancer
Adding pegvorhyaluronidase alfa to treatment with nab-paclitaxel and gemcitabine did not improve survival in adults with previously untreated metastatic pancreatic ductal adenocarcinoma in a phase 3 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Is Adenocarcinoma an Aggressive Cancer?
Title: Is Adenocarcinoma an Aggressive Cancer?Category: Diseases and ConditionsCreated: 7/30/2020 12:00:00 AMLast Editorial Review: 7/30/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 30, 2020 Category: Cancer & Oncology Source Type: news

Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
Prospective study shows increased risk for esophageal, gastric adenocarcinoma in two large cohorts (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 21, 2020 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Infections, Internal Medicine, Oncology, ENT, Journal, Source Type: news

Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
TUESDAY, July 21, 2020 -- Periodontal disease and tooth loss, indicative of oral microbial dysbiosis, are associated with esophageal and gastric adenocarcinoma, according to a research letter published online July 20 in Gut. Chun-Han Lo, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 21, 2020 Category: Pharmaceuticals Source Type: news

Scientists reveal comprehensive proteomic map of human lung adenocarcinoma
(Chinese Academy of Sciences Headquarters) A team of Chinese scientists from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, National Center for Protein Sciences (Beijing), National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Shanghai Jiao Tong University, recently reported a comprehensive proteomic analysis based on 103 Chinese patients with lung adenocarcinoma (LUAD), a leading cause of death among all types of cancer worldwide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2020 Category: Cancer & Oncology Source Type: news

New guideline: Don't routinely screen for EAC in patients with chronic GERD
(Canadian Medical Association Journal) A new guideline from the Canadian Task Force on Preventive Health Care, based on a rigorous systematic review of the latest evidence, found no benefit of routine screening for esophageal adenocarcinoma (EAC) and precursor conditions (Barrett esophagus and dysplasia) in patients with chronic gastroesophageal reflux disease (GERD). The guideline, published in CMAJ (Canadian Medical Association Journal), recommends physicians in Canada continue current practice to not screen routinely http://www.cmaj.ca/lookup/doi/10.1503/cmaj.190814. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 6, 2020 Category: Cancer & Oncology Source Type: news

Primary Gastric Adenocarcinoma Cells Have Distinct Gene-Expression Profiles Primary Gastric Adenocarcinoma Cells Have Distinct Gene-Expression Profiles
Primary gastric adenocarcinoma cells can be divided into five subgroups based on their gene-expression profiles, researchers in China report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncotarget: The role of EGFR mutations in predicting recurrence in lung adenocarcinoma
(Impact Journals LLC) Volume 11, Issue 22 of @Oncotarget reported that while lobectomy can improve mortality in this group, about 30 55% of patients will experience disease recurrence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2020 Category: Cancer & Oncology Source Type: news

AI can aid radiologists in detecting pancreatic cancer
An artificial intelligence (AI) algorithm helped radiologists from Taiwan improve...Read more on AuntMinnie.comRelated Reading: ASTRO updates guidance on pancreatic cancer CT perfusion shows promising utility in cancer treatment Cinematic rendering tops CT to visualize patient anatomy Can radiomics detect pancreatic ductal adenocarcinoma? Case report: Necrotizing pancreatitis after SAE (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 1, 2020 Category: Radiology Source Type: news

Updated data demonstrate Roche ’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer
Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented updated data from the pivotal phase III ALEX study, showing an increased five-year survival rate with Alecensa ® (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials. Full findings were presented at the ASCO2 0 Virtual Scientific Programme, on 29 May 2020.“These data further support Alecensa as the standard of care for people with metastatic AL...
Source: Roche Media News - May 29, 2020 Category: Pharmaceuticals Source Type: news

Trastuzumab combined with trimodality treatment does not improve outcomes for patients
(NRG Oncology) Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

CSIC researchers use whole living cells as 'templates' to seek for bioactive molecules
(Spanish National Research Council (CSIC)) A study performed by researchers at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) from the Spanish National Research Council (CSIC) pioneers the use of whole living cells (human lung adenocarcinoma) in dynamic combinatorial chemistry systems. This research, published in the journal Angewandte Chemie International Edition, proposes a new methodology to discover new bioactive molecules in a realistic biological medium. This methodology could help in the future to develop methods to differentiate healthy versus cancer cells, or to protect the extracellular matrix agai...
Source: EurekAlert! - Biology - May 27, 2020 Category: Biology Source Type: news

Platinum Therapy May Up Survival in Pancreatic Cancer With DNA Repair Defects
TUESDAY, May 26, 2020 -- For patients with advanced-stage pancreatic ductal adenocarcinoma (PDAC), those with homologous recombination deficiency (HRD) have improved survival with first-line (1L) platinum treatment, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2020 Category: Pharmaceuticals Source Type: news

Why pancreatic ductal adenocarcinoma is so lethal
(Cold Spring Harbor Laboratory) Pancreatic ductal carcinoma is a fast growing and invasive cancer, and now scientists understand the molecular dance that makes it so deadly. CSHL researchers discovered factors that allow a pancreatic cell to lose its identity, turn into an aggressive cancer cell, and recruit surrounding cells to help it invade more effectively. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2020 Category: Cancer & Oncology Source Type: news

Esophageal, Gastric Adenocarcinomas After H. pylori Infection Esophageal, Gastric Adenocarcinomas After H. pylori Infection
Does treatment and eradication of H pylori reduce the risk of future esophageal and proximal gastric cancer?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Professionals Analyze Pathology Following lung Lobectomies for Adenocarcinoma
Researchers examined the pathology of early-phase COVID-19 pneumonia in two older patients who were admitted to the hospital for adenocarcinoma procedures, but did not exhibit COVID-19 symptoms at the time of these procedures. (Source: CancerNetwork)
Source: CancerNetwork - April 14, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Cysteine depletion induces pancreatic tumor ferroptosis in mice
Ferroptosis is a form of cell death that results from the catastrophic accumulation of lipid reactive oxygen species (ROS). Oncogenic signaling elevates lipid ROS production in many tumor types and is counteracted by metabolites that are derived from the amino acid cysteine. In this work, we show that the import of oxidized cysteine (cystine) via system xC– is a critical dependency of pancreatic ductal adenocarcinoma (PDAC), which is a leading cause of cancer mortality. PDAC cells used cysteine to synthesize glutathione and coenzyme A, which, together, down-regulated ferroptosis. Studying genetically engineered mice,...
Source: ScienceNOW - April 1, 2020 Category: Science Authors: Badgley, M. A., Kremer, D. M., Maurer, H. C., DelGiorno, K. E., Lee, H.-J., Purohit, V., Sagalovskiy, I. R., Ma, A., Kapilian, J., Firl, C. E. M., Decker, A. R., Sastra, S. A., Palermo, C. F., Andrade, L. R., Sajjakulnukit, P., Zhang, L., Tolstyka, Z. P., Tags: Cell Biology, Medicine, Diseases reports Source Type: news

10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer
MONDAY, March 23, 2020 -- For men with intermediate- and high-risk prostate adenocarcinoma, 10-year outcomes are similar with conventionally fractionated intensity-modulated radiation therapy (C-IMRT) or moderate hypofractionated IMRT (H-IMRT),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2020 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
RARITAN, NJ, March 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.[1...
Source: Johnson and Johnson - March 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pancreatic Cancer Patients May Harbor Treatable Germline Mutations Pancreatic Cancer Patients May Harbor Treatable Germline Mutations
Germline mutations commonly found in individuals with pancreatic ductal adenocarcinoma (PDAC) may be treatable and should be identified as soon as possible, a comprehensive review suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 3, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis
Non–small cell lung cancer (NSCLC) is often characterized by mutually exclusive mutations in the epidermal growth factor receptor (EGFR) or the guanosine triphosphatase KRAS. We hypothesized that blocking EGFR palmitoylation, previously shown to inhibit EGFR activity, might alter downstream signaling in the KRAS-mutant setting. Here, we found that blocking EGFR palmitoylation, by either knocking down the palmitoyltransferase DHHC20 or expressing a palmitoylation-resistant EGFR mutant, reduced activation of the kinase PI3K, the abundance of the transcription factor MYC, and the proliferation of cells in culture, as we...
Source: Signal Transduction Knowledge Environment - March 2, 2020 Category: Science Authors: Kharbanda, A., Walter, D. M., Gudiel, A. A., Schek, N., Feldser, D. M., Witze, E. S. Tags: STKE Research Articles Source Type: news

HPV Biomarkers Linked to Improved Survival With Esophageal Dysplasia, Adenocarcinoma HPV Biomarkers Linked to Improved Survival With Esophageal Dysplasia, Adenocarcinoma
Human papillomavirus (HPV) positivity and HPV biomarkers are associated with improved survival in adults with Barrett high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC), according to a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 21, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

When a Promising Trial Fails, It Can Feel Personal When a Promising Trial Fails, It Can Feel Personal
Dr Mark Lewis shares how even with disappointing trial results, he remains hopeful that continuing research will craft a better present and future for our patients with pancreatic adenocarcinoma.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Overall survival in patients with lung adenocarcinoma harboring 'niche' mutations
(Impact Journals LLC) Mutations were observed in all genes studied, except c-MET, DDR2, MAP2K1, and RET.The multivariable analysis showed that:Niche mutations had higher mortality than EGFR mutationsKRAS mutations had higher mortality than EGFR mutations, andNiche mutations presented similar mortality to KRAS mutations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 4, 2020 Category: Cancer & Oncology Source Type: news